Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mythic Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units. This suggests that the company's therapeutic research involves multiple distinct biological or chemical platforms. The involvement of 2 distinct art units indicates that the applications likely fall under different technical classifications within the pharmaceutical field, requiring specialized arguments for each.
DUFFY, BRADLEY is the busiest examiner for the portfolio, currently managing 1 pending office action. With 2 distinct examiners each handling a portion of the 2 pending office actions, the prosecution workload is distributed. This means that no single individual dominates the current prosecution landscape. Practitioners must prepare for different examiner perspectives, as each pending office action is subject to individual interpretation of the prior art and examination standards.
For a practitioner, managing 2 pending office actions across 2 distinct art units requires adapting to different examination environments. Since DUFFY, BRADLEY only holds 1 pending action, the administrative burden is shared across the portfolio. This variety in examiners and art units may require tailored responses for each specific technical area rather than a unified strategy. Monitoring the specific trends in both distinct art units will be essential for successful outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | — | Pending | Dec 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMythic Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Estella M Gustilo has the most, with 1 of Mythic Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
